Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Eron

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
Plos One|February 27, 2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infectionNancie M Archin, Manzoor Cheema, Daniel Parker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2004
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patientsRobin Wood, Joseph Eron, Keikawus Arasteh, et al.
Plos One|July 5, 2012
Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010Hao Zhu, Sonia Napravnik, Joseph Eron, et al.
Journal of Virology|March 4, 2011
Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cellsJeffrey A Anderson, Nancie M Archin, William Ince, et al.
Cancer Epidemiology|November 4, 2011
High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible?Julius Atashili, Adaora A Adimora, Peter M Ndumbe, et al.
BMC Research Notes|October 31, 2012
Age trends in the prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Cameroon: a cross-sectional studyJulius Atashili, William C Miller, Jennifer S Smith, et al.
Plos One|July 10, 2010
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionPhilip M Grant, Lauren Komarow, Janet Andersen, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patientsRobin Wood, Keikawus Arasteh, Hans-Jürgen Stellbrink, et al.
Antiviral Therapy|August 26, 2009
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007Christopher B Hurt, Sandra I McCoy, Joann Kuruc, et al.
AIDS (London, England)|November 12, 2014
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trialsFrançois Raffi, Anita Rachlis, Cynthia Brinson, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
Plos One|February 27, 2010
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infectionNancie M Archin, Manzoor Cheema, Daniel Parker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2004
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patientsRobin Wood, Joseph Eron, Keikawus Arasteh, et al.
Plos One|July 5, 2012
Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010Hao Zhu, Sonia Napravnik, Joseph Eron, et al.
Journal of Virology|March 4, 2011
Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cellsJeffrey A Anderson, Nancie M Archin, William Ince, et al.
Cancer Epidemiology|November 4, 2011
High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible?Julius Atashili, Adaora A Adimora, Peter M Ndumbe, et al.
BMC Research Notes|October 31, 2012
Age trends in the prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Cameroon: a cross-sectional studyJulius Atashili, William C Miller, Jennifer S Smith, et al.
Plos One|July 10, 2010
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionPhilip M Grant, Lauren Komarow, Janet Andersen, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patientsRobin Wood, Keikawus Arasteh, Hans-Jürgen Stellbrink, et al.
Antiviral Therapy|August 26, 2009
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007Christopher B Hurt, Sandra I McCoy, Joann Kuruc, et al.
AIDS (London, England)|November 12, 2014
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trialsFrançois Raffi, Anita Rachlis, Cynthia Brinson, et al.
Pageof 7